SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
16 references·0 citing·51 second hop
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives (2020)Cost-Effectiveness of Tucatinib in Human …United States Life Tables, 2021 (2023)United States Life Tables, 20…United States Life Tables, 2020 (2022)United States Life Tables, 20…First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma (2019)First-line Nivolumab Plus Ipi…Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2018)Cost-effectiveness of afatini…The high price of anticancer drugs: origins, implications, barriers, solutions (2017)The high price of anticancer …Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives (2017)Economic evaluation of nivolu…Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States (2017)Early detection and curative …Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system (2016)Economic burden related to ch…Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2015)Cost-Effectiveness of Pertuzu…Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)Cost-Effectiveness Analysis o…Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Updating Cost-Effectiveness —…Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial (2013)Survival Modeling for the Est…INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES (2012)INCIDENCE-BASED COST-OF-ILLNE…Improved curve fits to summary survival data: application to economic evaluation of health technologies (2011)Improved curve fits to summar…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Methods for the economic evaluation of health care programmes (1987)Methods for the economic eval…Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)Decision Modelling For Health Economic Evaluation (2006)Practical methods for incorporating summary time-to-event data into meta-analysis (2007)Overview of Parametric Survival Analysis for Health-Economic Applications (2013)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆ (2017)Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer (2018)Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China (2021)Willingness to Pay for a Quality-adjusted Life Year (2000)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Economics and mental health: the current scenario (2020)Are Mortality Rates Falling at Extremely High Ages? An Investigation Based on a Model Proposed by Coale and Kisker (1995)Educational differentials in mortality: United States, 1979–1985 (1996)Lessons from 60 years of pharmaceutical innovation (2009)Race, socioeconomic status, and health: Complexities, ongoing challenges, and research opportunities (2010)A convenient approximation of life expectancy (the “DEALE”) (1982)Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C (2004)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis (2018)Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma (2019)Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (2021)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access (2021)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval (2024)Measuring and explaining the change in life expectancies (1984)Demography, Measuring and Modeling Population Processes (2002)The economic burden of child maltreatment in the United States, 2015 (2018)Mortality in the United States, 2021 (2022)Provisional Life Expectancy Estimates for 2021 (2022)United States Life Tables, 2019. (2022)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer (2020)Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (2021)Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)Measurement of health state utilities for economic appraisal (1986)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)The Estimation of a Preference-Based Measure of Health From the SF-12 (2004)
this work references cited by second hop

References

  • 1987Methods for the economic evaluation of health care programmes4,318 cited
  • 2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,303 cited
  • 2017The high price of anticancer drugs: origins, implications, barriers, solutions442 cited
  • 2023United States Life Tables, 2021385 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2011Improved curve fits to summary survival data: application to economic evaluation of health technologies308 cited
  • 2022United States Life Tables, 2020248 cited
  • 2019First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma150 cited
  • 2013Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial136 cited
  • 2017Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States125 cited
  • 2015Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer115 cited
  • 2015Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer94 cited
  • 2012INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES76 cited
  • 2018Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

71 cited
  • 2016Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system70 cited
  • 2017Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives55 cited
  • Cited by

    No citing works inside the corpus for this window.